Biotech companies to increase R&D spend but highlight complexity of clinical trials - ICON.

The article reports that ICON plc has released a whitepaper titled "Optimizing Biotech Funding," presenting insights into the current landscape of biotech companies and strategies for research and development (R&D) funding utilization. It mentions a survey included in the whitepaper reveals that 60 percent of biotech executives plan to increase R&D spending, with only 2 percent intending to reduce funding, while 32 percent identify clinical trials as a major challenge.